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OGTT-Derived Measures of Insulin Sensitivity Are Confounded by
Factors Other Than Insulin Sensitivity Itself
Abstract
Insulin resistance is an important risk factor for diabetes and other diseases. It has been important to estimate
insulin resistance in epidemiological and genetic studies involving significant number of individuals. Complex
and invasive protocols are impractical. Therefore, insulin sensitivity indices based on the oral glucose-
tolerance test (OGTT) have been introduced. The aim of the present study was to assess the accuracy with
which OGTT-derived indices would reflect changes in insulin sensitivity in the face of changes in other factors,
such as rate of glucose absorption and/or B-cell function. A computer model was employed to predict
excursions of plasma glucose and insulin after a 75-g oral glucose load. The model was then used to predict
changes in these excursions, which would be observed with altered insulin resistance, with alterations in β-cell
sensitivity to glucose and/or alterations in glucose absorption rates. Published indices of insulin sensitivity
could then be calculated from the predicted curves, to ask whether changes in β-cell function or glucose
absorptions rates might be misinterpreted (using the indices) as changes in insulin sensitivity. The model
accurately represented OGTT data for a normal glucose tolerant subject, closely matching published data.
Imposed 50% reductions or increases in insulin sensitivity alone in the model were reflected in only small
changes in OGTT-derived insulin sensitivity values. More important, imposed alterations in β-cell sensitivity
and glucose absorption without simulated changes in insulin sensitivity did change insulin sensitivity indices.
These results indicate that caution is required for the interpretation of differences in OGTT-derived values of
insulin sensitivity, because variation in factors other than insulin sensitivity per se appear to have the greatest
effects on indices calculated from the OGTT alone.
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OGTT-DERIVED MEASURES OF INSULIN SENSITIVITY ARE
CONFOUNDED BY FACTORS OTHER THAN INSULIN
SENSITIVITY ITSELF
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Abstract
Insulin resistance is an important risk factor for diabetes and other diseases. It has been important
to estimate insulin resistance in epidemiological and genetic studies involving significant number
of individuals. Complex and invasive protocols are impractical. Therefore insulin sensitivity
indices based upon the oral glucose tolerance test have been introduced. The aim of the present
study was to assess the accuracy with which OGTT-derived indices would reflect changes in
insulin sensitivity in the face of changes in other factors, such as rate of glucose absorption and/or
B-cell function. A computer model was employed to predict excursions of plasma glucose and
insulin after a 75g oral glucose load. The model was then used to predict changes in these
excursions which would be observed with altered insulin resistance, with alterations in b-cell
sensitivity to glucose, and/or alterations in glucose absorption rates. Published indices of insulin
sensitivity could then be calculated from the predicted curves, to ask whether changes in b-cell
function or glucose absorptions rates might be misinterpreted (using the indices) as changes in
insulin sensitivity. The model accurately represented OGTT data for a normal glucose tolerant
subject, closely matching published data. Imposed 50% reductions or increases in insulin
sensitivity alone in the model were reflected in only small changes in OGTT-derived insulin
sensitivity values. More important, imposed alterations in beta-cell sensitivity and glucose
absorption without simulated changes in insulin sensitivity did change previously published
insulin sensitivity indices. These results indicate that caution is required for the interpretation of
differences in OGTT-derived values of insulin sensitivity, because variation in factors other than
insulin sensitivity per se appear to have the greatest effects on indices calculated from the OGTT
alone.
Introduction
Insulin resistance is a central feature of the metabolic syndrome, the clustering of central
body obesity, impaired glucose tolerance, hypertension and dyslipidemia. The syndrome is
associated with a several-fold increase in diabetes and cardiovascular morbidity and
mortality. Incidence of the metabolic syndrome has been rapidly growing and is reaching
epidemic proportions with a major impact on public health. Consequently many research
projects are focused on insulin resistance and its complications. A fundamental requirement
for this research is the ability to accurately assess insulin sensitivity in large cohorts.
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Methods developed in the research laboratory are often not applicable in large populations.
One example is the hyperinsulinemic-euglycemic clamp test. Although considered the “gold
standard” for in vivo quantification of insulin sensitivity (1) this technique is time
consuming, costly and experimentally demanding. Another widely applied technique is the
minimal model (2), which determines insulin sensitivity from analysis of a frequently-
sampled intravenous glucose tolerance test (FSIGT). The latter method is less labor-
intensive than the euglycemic clamp and has been used for large studies (3,4). However, the
FSIGT can also be expensive, as glucose and insulin measurements usually are made from
multiple blood samples taken over a 3-h period.
There has been a search for simpler but still accurate methods for the quantification of
insulin sensitivity, which are applicable in large cohorts. The most widely used surrogate
measures of insulin action in epidemiologic studies of cardiovascular disease and diabetes
are based upon fasting blood measurements only; among these are fasting insulin per se, the
homeostatic model assessment (HOMA (5)) and the quantitative insulin sensitivity check
index (QUICKI (6)). However, there are problems associated with the use of fasting-based
measures. HOMA and QUICKI are mathematically related and provide essentially identical
information (7). HOMA reflects hepatic rather than peripheral insulin resistance (8). Also,
the genetic basis of HOMA has been differentiated from that of insulin sensitivity measured
directly from the FSIGT, suggesting that HOMA and the minimal model do not measure
genetic contribution to insulin resistance per se, but capture shared environmental
components (9). One possible reason that fasting insulin-based indices appear different from
direct measures of insulin action is that fasting insulin reflects not only insulin sensitivity,
but also insulin secretion as well as metabolic clearance of the hormone. Therefore the
plasma measurement alone will not accurately reflect insulin sensitivity in subjects with
beta-cell dysfunction (7,10). The accuracy of indices of insulin sensitivity purely based on
fasting measures has not been fully proven and is still a matter for discussion.
Given the previously stated limitations, it would be attractive to exploit the oral glucose
tolerance test (OGTT) to measure insulin sensitivity. A multiplicity of mathematical
representations calculating insulin sensitivity from glucose and insulin excursions after oral
glucose ingestion have been introduced (11-15). These published relations exploit the time
courses of glucose and insulin following glucose ingestion to calculate insulin action by a
variety of formulae. However, not only insulin sensitivity per se, but other biological
processes also affect plasma patterns of glucose and insulin after glucose ingestion. These
include the rate of glucose absorption, endogenous insulin secretion in response to glucose
and incretins, as well as insulin-independent effects of glucose on glucose uptake and
production (16,17). Thus in contrast to insulin sensitivity calculated from the glucose clamp,
insulin sensitivity derived from an OGTT could potentially be confounded by physiologic
factors separate from insulin resistance itself.
It is difficult experimentally to determine the relative importance of factors other than
insulin resistance per se on surrogate insulin resistance indices, which are based upon the
oral glucose tolerance test. One approach to assessment of the important of other factors
compared to insulin resistance itself is to use computer modeling. One can accurately
simulate the OGTT with a physiologically based model. Then, using the model, one
examines the predicted effects of various physiological processes (e.g., glucose absorption)
on the shape of the OGTT, and insulin resistance calculated from specific formulas. Here we
introduce such a model, and predict the effects of changes in various physiological
parameters upon OGTT indices proposed to reflect insulin resistance per se. The study
model suggests that it is difficult if not impossible to interpret changes in the OGTT in terms
of a single metabolic process such as insulin sensitivity itself. Therefore, indices of insulin
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resistance from the OGTT must be employed with extreme caution and under limited
conditions.
Methods
Mathematical simulation of in vivo glucose and insulin metabolism during an OGTT
The computer model we used is based upon previously validated mathematical models of
glucose kinetics (18) and insulin kinetics (19) which incorporate known physiology. The
complete model is shown in Figure 1. Glucose kinetics were described using the model of
Ni et al. (18) which was based on the work from Cobelli and colleagues (20). This model
assumes a two-compartment configuration with hepatic glucose output (HGO) described as
a linear function dependent on both the ambient glucose concentration and the effect of
insulin.
Equations 1, 2 and 3, below, represent factors, which control the plasma glucose
concentration. That is, the rate of change of plasma glucose is given by
(1)
Compartment G1 represents the concentration of glucose in plasma and tissues that rapidly
equilibrate with plasma (mg/dl, insulin insensitive), while G2 represents the mass of glucose
in tissues that slowly equilibrate with plasma (mg, insulin sensitive). VG is the volume of the
extracellular space (glucose distribution volume). Abs(t) is the rate of absorption of glucose
from the gastrointestinal tract and HGO(t) is the endogenous glucose production rate. K
parameters are fractional transfer coefficients as shown in Figure 1 (min-1). The rate of
appearance of glucose in the extravascular compartment is given by
(2)
FX represents the fraction of the effect of interstitial insulin that acts to suppress endogenous
glucose output, while (1-FX) is the remaining fraction which accelerates glucose disposal
from the peripheral compartment. The rate of endogenous glucose production is limited by
plasma glucose (G1(t)) and interstitial insulin (X(t)).
(3)
HGO0 is the endogenous glucose output, which would obtain in the absence of effects of
interstitial insulin and/or plasma glucose to restrain glucose production. Rate of change of
plasma insulin is given by
(4)
S(t) is the moment-by-moment secretion rate of insulin from the pancreatic islets; FI is the
fractional clearance rate of secreted insulin by the liver. VI is the distribution volume of
insulin in the body. Ib is the basal (fasting) insulin concentration.
(5)
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The effect of insulin on glucose kinetics was modeled as a remote insulin effect, and was
partitioned into two components. As previously noted, parameter FX describes that fraction
of the remote insulin effect that suppresses hepatic glucose output by the liver, while (1-FX)
describes the effect to activate glucose utilization by insulin-sensitive tissues.
Plasma insulin kinetics were described using a one-compartment model as described by
Watanabe et al. (21). Pre-hepatic insulin secretion is a known input to this model. The
insulin secretion rate changes in proportion to the ambient glucose concentration, with Kβ
representing β-cell sensitivity to glucose.
The term (1-FI) describes the fraction of insulin secretion that survives hepatic transit, with
FI representing fractional hepatic insulin extraction. The plasma insulin concentration above
basal determined by this model is used to determine the effect of interstitial insulin, X(t).
Model parameters were derived for man from the literature (21,22). The model was used to
describe insulin and glucose excursions after a 75 g oral glucose load under various
simulated metabolic conditions; isolated 50% changes of various parameters (see below)
were imposed. Simulated glucose and insulin concentrations and their respective
incremental area under the curve (AUC) were compared with simulated OGTT-data
representative for the parametrically unaltered “normal” state.
Simulation 1
Normal glucose tolerant subjects: We used parameter values representative for the normal
state (Table 1). To evaluate whether the model predictions are consistent with experimental
data representing an “average” human subject, the glucose and insulin data produced by the
simulation were compared to real oral tolerance data obtained from the literature (Figure 2,
23).
Simulation 2
Insulin sensitivity: We examined the impact of changes in insulin sensitivity alone on
OGTT-data. Changes in insulin sensitivity were accomplished by modifying the effect of
insulin in the remote (interstitial) compartment on glucose disposal (Figure 1). Alterations in
insulin sensitivity were imposed by changing the value of p3 in Equation 5.
Simulation 3
Beta-cell sensitivity: The stimulatory effect of a change in glucose on beta-cell secretion is
described by Kβ. A 50% enhancement or reduction in parameter Kβ was imposed on the
model in order to simulate isolated changes in pancreatic insulin response to glucose.
Simulation 4
Intestinal glucose absorption: While the total rate of glucose absorption was scaled by
50%, insulin sensitivity, beta-cell sensitivity to glucose and glucose effectiveness were kept
constant.
Simulation 5
Constant intestinal load absorbed, with change in absorption profile: To illustrate the
impact of changing the glucose absorption profile without affecting the total glucose load
absorbed, two profiles of glucose absorption were extracted from literature (23,24). These
profiles were chosen because the individuals were normal, and frequent samples of blood
had been taken during the OGTT. On average, the rate of glucose absorption in normal
patients obtained by Tillil et al (23) was faster than the rate of absorption extracted from
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Basu et al. (24). The slower glucose absorption rate resulted in longer absorption time
interval in the latter study (400 minutes) for the same amount of glucose load (75 g glucose)
to be absorbed. Thus, use of the two profiles allowed us to examine effect of absorption in
separate individuals. The total glucose load absorbed was 99% identical between the two
studies
OGTT-derived indices of insulin sensitivity
Based on the simulated glucose and insulin excursions, published indices of insulin
sensitivity (Table 2) were calculated. Indices applied here have been used in 10 or more
published articles. The indices used were the following:
Insulin120 min—The plasma insulin concentration [mU/l] 120 minutes after the oral
glucose challenge (11).
Matsuda-index—This index combines two terms that account for insulin sensitivity of the
hepatic as well as the peripheral tissues. One part of the equation consists of a hyperbolic
conversion of the product of fasting plasma glucose and insulin as a measure of hepatic
sensitivity. The second term accounts for whole-body insulin sensitivity, which is described
by the inverse product of the mean glucose and insulin concentration after the glucose load
(14).
ISI(0,120)-index—In this mathematical relation, insulin sensitivity is expressed as the ratio
between glucose uptake rate and the logarithmic transformation of serum insulin
concentration. Glucose uptake rate in peripheral tissue is expressed as the difference
between the administered glucose and the remaining glucose in the glucose space after 120
minutes. Effects of glucose on glucose disposal are accommodated by dividing glucose
uptake rate by the mean plasma glucose concentration (13).
OGIS120—Mari et al. developed a model based OGTT-index. The equations are derived
from a simplified physiological model of insulin and glucose dynamics, which is constructed
on established principles of glucose kinetics and insulin action (11).
Results
Simulation of OGTT
The model-simulated glucose and insulin time courses accurately mimicked average OGTT
glucose and insulin profiles derived from normal glucose tolerant individuals (Figure 2, 23).
Residual patterns indicate the model-simulated glucose accurately reflected the average
glucose and insulin data (data not shown).
Results of changes in individual variables on OGTT profiles
Insulin Sensitivity—Imposing a 50% reduction of insulin sensitivity increased predicted
plasma glucose during the OGTT (Figure 3A, Table 3). The incremental area under the
curve (AUC) for glucose increased 31% leading to a concomitant 10% increase in insulin
AUC, even though sensitivity of the beta-cell to glucose was not altered in this simulation.
Conversely, a simulated 50% increase in insulin sensitivity lowered predicted incremental
glucose (incremental AUCglucose: -17%) and plasma insulin excursions (incremental
AUCinsulin: -5%).
Beta-cell sensitivity to glucose—When the simulated sensitivity of the beta-cell to
glucose was independently raised or reduced by 50%, the impact was proportionately higher
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or lower plasma insulin excursions respectively (Figure 3B,Table 3). Thus, with a 50%
reduction of beta-cell sensitivity, incremental AUC for insulin was reduced by 45%
accompanied by a 33% increase in the incremental AUC for plasma glucose due to reduced
glucose clearance and increased liver glucose production.
On the other hand, a simulated 50% increase in beta-cell sensitivity increased predicted
AUC for insulin by 42%, with a resultant 17% decline in the incremental AUC for glucose,
reflecting the simulated enhancement of glucose tolerance in the face of increased β-cell
function on glucose tolerance.
Glucose Absorption—The simulation of a reduction in glucose absorption resulted in the
most pronounced reduction of glucose and insulin plasma concentrations (Figure 3C, Table
3). Incremental AUC for glucose was reduced by as much as 79%. Because glucose levels
were diminished the insulin concentrations were also reduced (incremental AUCinsulin:
-26%). An alternative published pattern of glucose absorption (24) resulted in reduction of
the incremental AUC of insulin by 27%, and reduction of the glucose AUC by 32% (Figure
3D, Table 3).
Indices of insulin sensitivity
Values of the various indices of insulin action calculated from the simulated OGTT for a
normal individual (Simulation 1) were in agreement with published values: Sensitivity
values were 4.1 10-4 U*l-1ml*mg-1*ml for the Matsuda-index (2.9 to 6.0, (32-34)), 80.0
mg*l-2*mmol-1*mU*min for the ISI(0,120)-index (56 to 89, (14;34;35)), and 403.1
ml*min-1*m-2 for the OGIS120 (362 to 492, (12;36)).
Insulin Sensitivity—Table 4 summarizes the insulin sensitivity values calculated from
OGTT-data resembling a normal glucose tolerant individual and the relative changes in the
calculated insulin sensitivity indices. When a 50% reduction in insulin sensitivity only was
imposed OGTT-derived sensitivity indices showed decreased sensitivity (Table 4).
However, the changes were not proportional, and generally underestimated the magnitude of
the changes in resistance. The Matsuda-index and the ISI(0,120)-index fell by 9% and
13.5% respectively, and the simple index measuring insulin concentration at 120 minutes
increased 14.4%. The OGIS index decreased by 2.5%. When an isolated 50% rise in insulin
sensitivity was imposed on the model the calculated OGTT-indices increased by an average
of only 2% (ranging from -5.9 (I120 index) to +6.8 % (ISI(0,120)-index)).
Beta-cell sensitivity to glucose—Isolated alterations in beta-cell sensitivity to glucose
(Simulation 3) led to striking and widely varied changes in the calculated sensitivity values,
even though simulated sensitivity per se did not change at all (Table 4). The 50% reduction
of beta-cell sensitivity was given as an 82% increase in insulin sensitivity by the Matsuda
index and given as a 43% decrease by the I120. The ISI(0,120) index went up by 12% while
the OGIS120 was only marginally affected (+3.3%). Simulation of a 50% increase in beta-
cell sensitivity led to pronounced changes in the I120 and the Matsuda-index (41% and
−30% respectively) but did not markedly affect the OGIS120.
Glucose Absorption—When simulated intestinal glucose absorption was reduced by
50% (Simulation 4), we observed pronounced increments in most of the calculated insulin
sensitivity indices, despite no change in the actual insulin sensitivity value (Table 4).
Lowering the amount of intestinal glucose absorption was misinterpreted as clear increase in
OGTT-based indices ranging from 7.4% (OGIS120) to 33% (ISI(0,120)- and Matsuda-
index)). Changing the profile of glucose absorption without a change in the total amount of
glucose absorbed also impacted the insulin sensitivity as calculated by the OGTT-derived
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indices; despite the fact that the only change was in the shape of the glucose absorption
profile. However the insulin sensitivity change was not concordant among various indices.
For example, I120 insulin sensitivity index indicated 47% decrease of insulin sensitivity,
while Matsuda index quantified the change in the glucose absorption profile as 36.7%
improvement in insulin sensitivity.
Discussion
The use of the OGTT for measuring insulin sensitivity bears several potential advantages:
OGTT is a widely used, straightforward test which given its simplicity, could in principle be
applicable in large populations. Another advantage is that the OGTT is performed under
rather physiological conditions with dynamic changes in glucose and insulin concentrations.
Several previous studies have shown significant correlations between insulin sensitivity
values derived from the OGTT and insulin sensitivity derived from the euglycemic clamp
(11,14,15). However, these previous studies were usually performed in metabolically normal
subjects, in whom insulin sensitivity was known to be correlated with adiposity as well as
insulin response. Therefore, previously reported correlations between OGTT indices and
direct sensitivity measurements by the glucose clamp may well reflect epiphenomena
wherein the adiposity and beta-cell compensation for resistance itself increased OGTT
indices due to compensation for resistance. If so, differences in beta-cell responsiveness
between ethnic groups, for example could render conclusions regarding insulin resistance
per se questionable.
Supporting the latter concept, several groups found somewhat weak correlations between
insulin sensitivity values derived from direct measurements and various OGTT-based
indices (11,25,26). In a cohort of 77 Japanese individuals with varying degrees of glucose
tolerance, Matsuda’s (r= 0.45) and ISI(0,120) (r= 0.53) formulas correlated only modestly
with clamp insulin sensitivity values (25). Also OGTT-derived indices were less likely to
detect differences in insulin sensitivity among different ethnic groups (Asian-, African-,
Caucasian-, and Mexico-Americans), while differences had been clearly established by
euglycemic clamp measurements (27). Furthermore, a recently published study reported that
the estimations of insulin sensitivity and beta-cell function by OGTT derived methods failed
to reproduce the hyperbolic relation between the latter factors (28), which has been well
established (29).
Beta-cell function is an important determinant of oral glucose tolerance in vivo. Indeed, in
the present study, 50% changes of beta-cell sensitivity resulted in almost equivalent changes
in integrated plasma insulin response (Table 3). Plasma insulin is a quantitatively important
component of most of the applied OGTT-formulae (Table 3). In the present study a
simulated reduction in beta-cell sensitivity only caused an attenuation of insulin excursions,
which resulted in a substantial overestimation of insulin sensitivity from published indices.
Conversely an increase in beta-cell sensitivity was misinterpreted as insulin resistance. This
indicates that the use of OGTT-derived indices will be confounded by differences in beta-
cell function.
It is established that a curvilinear relationship exists between insulin response and insulin
sensitivity (29). For any amount of insulin secreted by the pancreas, the biological response
of a given effector is dependent on its insulin sensitivity. Any decrease in insulin sensitivity
could result in increases in blood glucose concentrations that will act on the beta-cell to
produce a compensatory stimulus of insulin secretion, leading to a degree of
hyperinsulinemia that is approximately proportional to the degree of resistance. Thus,
plasma insulin concentrations during an OGTT simultaneously reflect these two
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interdependent physiological processes (insulin secretion and insulin sensitivity). Therefore
it could be argued that in individuals with comparable beta-cell function, insulin response
during an OGTT can be used as a surrogate for insulin sensitivity. However we also found
that a 50% reduction of beta-cell sensitivity resulted in pronounced overestimation of insulin
sensitivity by the OGTT-indices. These findings suggest OGTT-based indices will be less
capable of accurately measuring insulin sensitivity in subjects with even a subtle beta-cell
defect.
In the present simulation insulin “sensitivity” indices I120 and the Matsuda-index were most
vulnerable to isolated changes in beta-cell sensitivity. The I120 directly measures insulin
response during the OGTT and is therefore fully dependent on changes in insulin secretion.
The Matsuda-index contains the product of glucose and insulin concentrations (fasting and
during the OGTT) in the denominator. Therefore a fall in plasma insulin levels due to beta-
cell dysfunction will incorrectly increase the calculated sensitivity value, if the reduction in
insulin is not directly accompanied by an increase in plasma glucose levels. It has been
demonstrated that a reduction of plasma insulin levels is not necessarily translated into a rise
in glucose concentrations since other compensatory mechanisms attempt to maintain glucose
homeostasis. The impact of beta-cell function on the Matsuda index demonstrated in the
present study is confirmed by a number of previous investigations. When the Matsuda-index
was tested against the clamp in type 2 diabetic patients either no significant correlation (11)
or considerably lower coefficient of correlation (16) was found.
Recently, the Matsuda-index was used to estimate insulin sensitivity in children with cystic
fibrosis (30). Due to the underlying disease there was a 62% reduction in insulin areas under
the curve during the OGTT 13 years after diagnosis. The Matsuda index indicated a 175%
increased insulin sensitivity. But, recent clamp measurements in patients with cystic fibrosis
have documented decreased insulin sensitivity as the disease progresses (31-33). Therefore
it is likely that the reported apparent improvement of insulin sensitivity was an artifact of the
reduction of the insulin response to glucose due to beta-cell dysfunction.
The amount of glucose absorbed into the systemic circulation has a large impact on glucose
and insulin concentrations during the OGTT. It has been demonstrated that variation in
gastric emptying accounts for ~35% of the variance in peak blood glucose concentrations
after ingestion of oral glucose (16). Additional factors that determine the appearance of
glucose include mucosal absorption of glucose, small-intestinal motor patterns, and
splanchnic blood flow. Insulin levels are also dependent on the rate of glucose absorption
since glucose is a stimulus for insulin secretion. Additionally, insulin concentration after
oral glucose is influenced by incretins.
We found that a simulated isolated reduction in glucose absorption resulted in diminished
post-load glucose and insulin excursions. As a consequence, OGTT-based indices
misinterpreted a reduction of intestinal glucose absorption as an increase in insulin
sensitivity. The strong effect of glucose absorption on OGTT-derived insulin sensitivity
values in the present study is supported by OGTT-data from human subjects: Intestinal
glucose absorption was reduced by a one-time administration of the alpha-glucosidase
inhibitor acarbose both in healthy subjects (34) and in patients with type 2 diabetes (35).
Calculated OGTT-derived sensitivity indices were up to 50% higher in the acarbose
experiments (Table 5) even though a single dose of acarbose does not affect insulin
sensitivity (36). Moreover, a change in the absorption profile without changing the total
intestinally absorbed load had a similar impact on the OGTT-derived indices as the 50%
reduction in total absorbed glucose. A majority of OGTT-derived indices inaccurately
reported the change in the absorption profile as a change in insulin sensitivity.
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In the present study we employed a computer model to investigate effects of various
metabolic factors on OGTT-derived insulin sensitivity. We found that OGTT-derived
indices presently available largely underestimate isolated changes in insulin sensitivity.
Also, the simulation indicates that beta-cell function and patterns and/or amounts of
intestinal glucose absorption have a very large impact on insulin sensitivity values
calculated from the OGTT.
The present study points out the limitations of OGTT-indices: Caution is required for the
interpretation of OGTT-derived insulin sensitivity values in clinical research because
differences in SIOGTT might reflect variations in beta-cell function, adiposity, and/or
glucose absorption rather than variations in insulin sensitivity. It is not clear that OGTT
based indices are superior to fasting insulin alone for measuring insulin sensitivity when
direct methods such as the euglycemic clamp, the minimal model or the pancreatic
suppression test cannot be used.
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Figure 1.
Simulation Model. Pre-hepatic insulin secretion and glucose absorption rates are “given”
inputs to the model. See text for details.
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Figure 2.
Plasma glucose and insulin excursions in response to an OGTT as predicted by our model
(solid line) closely matches the “real” glucose and insulin data (23). Residuals are shown in
the inserts.
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Figure 3.
Model simulation of plasma glucose and insulin concentrations in response to an oral
glucose load (75 g) under the assumption of a 50% increase (dashed line) or reduction (dot-
dashed line) in insulin sensitivity (A), beta-cell sensitivity (B), glucose absorption from the
intestine (C), or change in glucose absorption profile (D).
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Figure 4.
Known glucose absorption and insulin secretion rates. Top panel shows the assumed gut
glucose absorption rate over the course of the OGTT. Bottom panel shows the pre-hepatic
insulin secretion rates.
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Figure 5.
Two different glucose absorption profiles pertaining to normal population of humans.
Glucose absorption aquired from Tillil et al. (23), solid line, and glucose absorption profile
extracted from Basu et al. (24), dashed line.
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Table 1
Parameter values used for simulation of OGTT insulin and glucose concentrations in the normal state.
Model Parameter Unit Value
F fraction 0.5
KI min-1 0.175
VI L 4.55
KG fraction per mg/dl 0.009
K21 min-1 0.043
K12 min-1 0.059
K01 min-1 0.012
K02 min-1 0.0055
KL min-1 0.00917
p2 min-1 0.02
p3 min-2 per μU/ml 0.00001
FX fraction 0.01
VG dl 11.4
HGO(0) mg/min 274.4
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Table 2
OGTT-derived indices of insulin sensitivity and their coefficient of correlation (r) between SIOGTT and Siclamp
from the study that introduced the respective composite (n= total number of subject in the study).
INSULIN SENSITIVITY INDICES EQUATION N R REF.
I120 Insulin at 120 min 104 0.62 (15)
Matsuda index 153 0.73 (14)
ISI(0,120)-Index 135 0.63 (13)
OGIS120 Glucose-insulin model 91 0.77 (11)
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